文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

PAF 诱导的炎症和免疫过敏性眼病及其 PAF 受体拮抗剂的缓解作用:细胞和核效应。

PAF-induced inflammatory and immuno-allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects.

机构信息

Singapore Eye Research Institute (SERI), Singapore, Singapore.

Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, Texas, USA.

出版信息

Biofactors. 2022 Nov;48(6):1226-1249. doi: 10.1002/biof.1848. Epub 2022 May 20.


DOI:10.1002/biof.1848
PMID:35594054
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10084252/
Abstract

Ocular allergies are becoming more prevalent as more airborne pollutants, irritants and microbes pervade our environment. Inflammatory and allergic mediators released by dendritic and mast cells within the conjunctiva cause allergic conjunctivitis (AC), a prevalent ocular surface disorder that affects >40% of the world's human population on a seasonal or perennial basis. Even though histamine is a major culprit, platelet-activating factor (PAF) also contributes to AC, acting either directly or synergistically with histamine and other mediators. PAF receptor-meditated inflammatory reactions, via cell-membrane-bound and nuclear-membrane-bound and nuclear PAF receptors, are also implicated in the etiology of other eye diseases such as uveitis, diabetic retinopathy, corneal and choroidal neovascularization, and age-related macular degeneration which cause serious visual impairment and can lead to blindness. This review highlights the various deleterious elements implicated in the pathological aspects of ocular allergic reactions and inflammation and provides concepts and treatment options to mitigate these eye disorders with a special focus on PAF and PAF receptor antagonists.

摘要

随着越来越多的空气污染物、刺激物和微生物弥漫在我们的环境中,眼部过敏变得越来越普遍。结膜中的树突状细胞和肥大细胞释放的炎症和过敏介质会导致过敏性结膜炎 (AC),这是一种常见的眼表疾病,影响全球超过 40%的人口,无论是季节性的还是常年性的。尽管组胺是主要罪魁祸首,但血小板激活因子 (PAF) 也会导致 AC,它通过与组胺和其他介质直接或协同作用来发挥作用。PAF 受体介导的炎症反应通过细胞膜结合和核膜结合以及核 PAF 受体也与其他眼部疾病(如葡萄膜炎、糖尿病性视网膜病变、角膜和脉络膜新生血管形成以及年龄相关性黄斑变性)的发病机制有关,这些疾病会导致严重的视力损害,并可能导致失明。本综述强调了眼部过敏反应和炎症的病理方面涉及的各种有害因素,并提供了概念和治疗选择,以减轻这些眼部疾病,特别关注 PAF 和 PAF 受体拮抗剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/0938338b117e/BIOF-48-1226-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/9aa7eedf40e7/BIOF-48-1226-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/53c753c91f27/BIOF-48-1226-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/ea59a9f1b71e/BIOF-48-1226-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/709a930716c9/BIOF-48-1226-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/23a0ba21b7e4/BIOF-48-1226-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/8404e30ceb86/BIOF-48-1226-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/af4b3974b42a/BIOF-48-1226-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/a44cfb9a0fa2/BIOF-48-1226-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/616e6ff98bbb/BIOF-48-1226-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/9a6bd66da755/BIOF-48-1226-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/6a52596e5ccd/BIOF-48-1226-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/0a71bfa04add/BIOF-48-1226-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/69fc1bef0fe7/BIOF-48-1226-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/d1b81eab48d6/BIOF-48-1226-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/7163e97d06d6/BIOF-48-1226-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/7380f3d10517/BIOF-48-1226-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/a8b3d044a893/BIOF-48-1226-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/eeceff511262/BIOF-48-1226-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/4eb18390e715/BIOF-48-1226-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/0938338b117e/BIOF-48-1226-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/9aa7eedf40e7/BIOF-48-1226-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/53c753c91f27/BIOF-48-1226-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/ea59a9f1b71e/BIOF-48-1226-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/709a930716c9/BIOF-48-1226-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/23a0ba21b7e4/BIOF-48-1226-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/8404e30ceb86/BIOF-48-1226-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/af4b3974b42a/BIOF-48-1226-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/a44cfb9a0fa2/BIOF-48-1226-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/616e6ff98bbb/BIOF-48-1226-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/9a6bd66da755/BIOF-48-1226-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/6a52596e5ccd/BIOF-48-1226-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/0a71bfa04add/BIOF-48-1226-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/69fc1bef0fe7/BIOF-48-1226-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/d1b81eab48d6/BIOF-48-1226-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/7163e97d06d6/BIOF-48-1226-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/7380f3d10517/BIOF-48-1226-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/a8b3d044a893/BIOF-48-1226-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/eeceff511262/BIOF-48-1226-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/4eb18390e715/BIOF-48-1226-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d15/10084252/0938338b117e/BIOF-48-1226-g011.jpg

相似文献

[1]
PAF-induced inflammatory and immuno-allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects.

Biofactors. 2022-11

[2]
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.

Exp Eye Res. 2010-4-20

[3]
Ocular actions of platelet-activating factor: clinical implications.

Expert Opin Ther Targets. 2012-8-27

[4]
Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor.

Ann Allergy Asthma Immunol. 2013-9-21

[5]
The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis.

J Ocul Pharmacol Ther. 2003-8

[6]
Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs.

J Pharmacol Sci. 2004-8

[7]
Involvement of chymase in allergic conjunctivitis of guinea pigs.

Exp Eye Res. 2013-5-28

[8]
Neuropathic pain and itch: mechanisms in allergic conjunctivitis.

Curr Opin Allergy Clin Immunol. 2022-10-1

[9]
Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.

Clin Exp Allergy. 2007-11

[10]
Diagnostics and new developments in the treatment of ocular allergies.

Curr Allergy Asthma Rep. 2012-6

引用本文的文献

[1]
Targeting Non-Eosinophilic Immunological Pathways in COPD and AECOPD: Current Insights and Therapeutic Strategies.

Int J Chron Obstruct Pulmon Dis. 2025-3-5

[2]
HSD17B13 liquid-liquid phase separation promotes leukocyte adhesion in chronic liver inflammation.

J Mol Cell Biol. 2024-11-25

[3]
How to handle off-label prescriptions of rupatadine, a second-generation antihistamine and PAF antagonist: a review.

Drugs Context. 2024-1-18

本文引用的文献

[1]
Laser-induced choroidal neovascularization detected on optical coherence tomography angiography in patients with diabetic retinopathy.

Am J Ophthalmol Case Rep. 2022-1-22

[2]
Update on Current and Future Management for Diabetic Maculopathy.

Ophthalmol Ther. 2022-4

[3]
Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.

Int Ophthalmol. 2022-6

[4]
Intravitreal Injection for Diabetic Macular Edema as Adjunctive Therapy for Proliferative Diabetic Retinopathy: A Retrospective Study.

Clin Ophthalmol. 2022-1-14

[5]
From prodrug to pro-prodrug: hypoxia-sensitive antibody-drug conjugates.

Signal Transduct Target Ther. 2022-1-21

[6]
New trends in intravitreal anti-VEGF therapy for ROP.

Eur J Ophthalmol. 2022-5

[7]
Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand-siRNA Conjugates.

ACS Chem Biol. 2022-2-18

[8]
Antibody-oligonucleotide conjugates enter the clinic.

Nat Rev Drug Discov. 2022-1

[9]
Rupatadine to prevent local allergic reactions to sublingual allergy immunotherapy: a case series.

Allergy Asthma Clin Immunol. 2021-12-4

[10]
Introduction to Antibody-Drug Conjugates.

Antibodies (Basel). 2021-10-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索